Fate Therapeutics, Inc. provided earnings guidance for the year ending December 31, 2022. For the period, the company expects its GAAP Loss from Operations to be between $335 million to $365 million, which loss includes stock-based compensation expense, and its cash use to be between $290 million to $315 million, which use excludes any amounts that may be received under its collaborations with Janssen and Ono in connection with the achievement of development milestones.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.3 USD | -5.60% | -18.41% | +14.97% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.97% | 489M | |
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.31% | 22.2B | |
-16.53% | 21.23B | |
-8.77% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022